Literature DB >> 18375247

Selenium inhibits high glucose- and high insulin-induced adhesion molecule expression in vascular endothelial cells.

Hong-Ting Zheng1, Li-Na Zhou, Chun-Ji Huang, Xing Hua, Rui Jian, Bei-Hai Su, Fang Fang.   

Abstract

BACKGROUND: Initiation of an atherosclerotic lesion requires endothelial expression of adhesion molecules. Selenium (Se), a biologically essential trace element, can inhibit cytokine (e.g., TNF-alpha)-induced expression of adhesion molecules. Atherosclerosis is accelerated in diabetic patients. This is at least partially caused by hyperglycemia and hyperinsulinemia increasing adhesion molecule expression. These experiments tested whether Se can also alter high glucose- and high insulin-induced expression of adhesion molecules.
METHODS: Human umbilical vein endothelial cells (HUVECs) were pretreated with Se and stimulated by high glucose or high insulin. Expression of adhesion molecules was measured by Western blot.
RESULTS: Se (100 nmol/L) significantly inhibited glucose (25 mmol/L)-induced expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin. Moreover, Se significantly inhibited insulin (100 nmol/L)-induced VCAM-1 and ICAM-1 expression, whereas high insulin had no inducing effect on E-selectin. Se also inhibited high glucose- and high insulin-induced activation of p38 mitogen-activated protein kinase (p38), which indicated that the preventive effects of Se on adhesion molecules may be associated with p38. The important role of p38 in Se effects was further confirmed using p38 inhibitor SB203580.
CONCLUSIONS: These results suggest that Se can inhibit high glucose- and high insulin-induced expression of adhesion molecules. Such antagonism is at least partially mediated through the modulation of p38 pathway. Therefore, Se may be considered as a potential preventive intervention for diabetes-accelerated atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375247     DOI: 10.1016/j.arcmed.2007.12.007

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

Review 1.  The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.

Authors:  Zhi Huang; Aaron H Rose; Peter R Hoffmann
Journal:  Antioxid Redox Signal       Date:  2012-01-09       Impact factor: 8.401

2.  Zinc deficiency decreased cell viability both in endothelial EA.hy926 cells and mouse aortic culture ex vivo and its implication for anti-atherosclerosis.

Authors:  Young-Eun Cho; Jee-Eun Choi; Md Jahangir Alam; Man-Hyo Lee; Ho-Yong Sohn; John H Beattie; In-Sook Kwun
Journal:  Nutr Res Pract       Date:  2008-06-30       Impact factor: 1.926

3.  Trace elements in glucometabolic disorders: an update.

Authors:  Nicolas Wiernsperger; Jeanrobert Rapin
Journal:  Diabetol Metab Syndr       Date:  2010-12-19       Impact factor: 3.320

4.  Effect of Selenium-Enriched Garlic Oil against Cytotoxicity Induced by OX-LDL in Endothelial Cells.

Authors:  Cheng Yang; Kai Cui; Yutao Diao; Min Du; Shumei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-29       Impact factor: 2.629

5.  CD226 reduces endothelial cell glucose uptake under hyperglycemic conditions with inflammation in type 2 diabetes mellitus.

Authors:  Yuan Zhang; Tian Liu; Yu Chen; Zilong Dong; Jinxue Zhang; Yizheng Sun; Boquan Jin; Feng Gao; Shuzhong Guo; Ran Zhuang
Journal:  Oncotarget       Date:  2016-03-15

6.  Identification of the Selenoprotein S Positive UGA Recoding (SPUR) element and its position-dependent activity.

Authors:  Eric M Cockman; Vivek Narayan; Belinda Willard; Sumangala P Shetty; Paul R Copeland; Donna M Driscoll
Journal:  RNA Biol       Date:  2019-08-21       Impact factor: 4.652

7.  The Gut Microbiome, Seleno-Compounds, and Acute Myocardial Infarction.

Authors:  Fu-Chun Chiu; Chin-Feng Tsai; Pang-Shuo Huang; Ching-Yu Shih; Mong-Hsun Tsai; Juey-Jen Hwang; Yi-Chih Wang; Eric Y Chuang; Chia-Ti Tsai; Sheng-Nan Chang
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.